Artemether/Lumefantrine and Vivax Malaria

Phase 3

Completed

• Conditions: Vivax Malaria
• Interventions: Drug: tablets artemether/lumefantrine

• Registration Number: NCT01625871
• Lead Sponsor: University of Khartoum

Brief Summary

The cure rate of artemether/lumefantrine in the treatment of vivax malaria.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09
• Study First Submitted: 2012-06-17
• Study First Submitted QC: 2012-06-19
• Study First Posted: 2012-06-22
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-16
• Last Update Posted: 2013-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Patients with vivax malaria

Read More

Exclusion Criteria

• severe malaria
• pregnancy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
artemether-lumefantrine	tablets artemether/lumefantrine	tablets (containing 20mg artemether and 120 mg lumefantrine) for three days

Primary Outcome Measures

Name	Time	Method
The cure rate	28 days	The proportion of the cure patients

Secondary Outcome Measures

Name	Time	Method
Fever clearance time	28 days	The time for fever clearance
Parasite clearance time	28 days	The time for the parasite to clear

Trial Locations

Locations (1)

Kassala; 🇸🇩 Kassala, Sudan